ERBB2 and breast cancer: For instance, during breast cancer progression, there is a progressive loss of FOXK2 expression, which correlates closely with poor prognostic indicators such as higher histological grade, lymph node positivity, and ERα−/PR−/HER2− status, highlighting its potential as a prognostic biomarker (23).